A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

Summary

The main purpose of the proposed study is to evaluate the efficacy of efgartigimod PH20 SC in patients with moderate-to-severe Primary Sjögren's Disease (pSjD). The study consists of a double-blinded placebo-controlled treatment period and an open-label treatment period. The maximum study duration for participants in both study parts is approximately 105 weeks.

Timeline

Start

2025-01-15

Primary completion

2027-07

Completion

2028-07

Drugs

Indications